Masaru Matsumura

12PUBLICATIONS
11CO-AUTHORS
Predictive and prognostic markersChemotherapyCancer diagnosisHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 03, 2025
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report.

Yusuke Kawamura, Norio Akuta, Junichi Shindoh

|Mar 19, 2025
Prognostic factors and clinical significance of preoperative systemic therapy in patients with borderline resectable hepatocellular carcinoma: A JSHBPS project study 2023, Part 2.

Junichi Shindoh, Masaru Matsumura, Shohei Komatsu

|Mar 17, 2025
A questionnaire survey to explore the current treatment policies adopted for patients with advanced hepatocellular carcinoma at board-certified HPB training institutions in Japan: A JSHBPS project study 2023, Part 1.

Junichi Shindoh, Masaru Matsumura, Satoshi Okubo

|Nov 29, 2024
Pancreatic groove cancer with large cystic lesion.

Daisuke Tomita, Masaru Matsumura, Kentoku Fujisawa

|Sep 26, 2024
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy.

Yusuke Kawamura, Norio Akuta, Junichi Shindoh

|Aug 12, 2023
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma.

Yusuke Kawamura, Norio Akuta, Junichi Shindoh

Pageof 2

Frequent Collaborators

4 joint publications

Junichi Shindoh

3 joint publications

Yusuke Kawamura

2 joint publications

Norio Akuta

2 joint publications

Tetsuya Hosaka